Home › Funds › Bellevue Group AG › RLAY
Bellevue Group AG position in RLAY
RELAY THERAPEUTICS INC COM · Health Care
Bellevue Group AG reported holding 6,185,970 shares of RLAY (RELAY THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$115.7M, representing 2.44% of its reported portfolio and ranking #11 among its reported holdings. Bellevue Group AG has disclosed RLAY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's RLAY position evolved
Bellevue Group AG first disclosed a stake in RLAY in Q3 2023 at 4,885,000 shares (US$41.1M). The position peaked in Q2 2026 at 6,185,970 shares, worth US$115.7M. Across 12 filings, Bellevue Group AG increased the stake 5 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 6,185,970 shares valued at US$115.7M — a reduction of -1,609,272 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 4.88M | $41.08M | New |
| Q4 2023 | 5.94M | $65.36M | Add |
| Q1 2024 | 5.93M | $49.19M | Hold |
| Q2 2024 | 6.38M | $41.58M | Add |
| Q3 2024 | 7.38M | $52.23M | Add |
| Q4 2024 | 7.38M | $30.39M | Hold |
| Q1 2025 | 7.38M | $19.33M | Hold |
| Q2 2025 | 8.23M | $28.48M | Add |
| Q3 2025 | 8.35M | $43.56M | Add |
| Q4 2025 | 8.35M | $70.60M | Hold |
| Q1 2026 | 7.80M | $77.56M | Reduce |
| Q2 2026 | 6.19M | $115.74M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RLAY and 13F data
RLAY (RELAY THERAPEUTICS INC COM) is a Health Care company. 64 other funds we track also report a position in RLAY — the largest reported positions include SB INVESTMENT ADVISERS (UK) LTD (US$522.1M), Casdin Capital (US$300.0M), PERCEPTIVE ADVISORS LLC (US$263.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RLAY
- SB INVESTMENT ADVISERS (UK) LTD 27.90M sh · $522.10M · Q2 2026
- Casdin Capital 16.04M sh · $300.02M · Q2 2026
- PERCEPTIVE ADVISORS LLC 14.11M sh · $263.93M · Q2 2026
- Commodore Capital LP 12.00M sh · $224.52M · Q2 2026
- Nextech Invest Ltd. 6.78M sh · $126.79M · Q2 2026
- TCG Crossover Management, LLC 4.27M sh · $79.95M · Q2 2026
- Siren, L.L.C. 3.65M sh · $68.29M · Q2 2026
- Kynam Capital Management, LP 3.30M sh · $61.74M · Q2 2026
- Spruce Street Capital LP 2.98M sh · $55.83M · Q2 2026
- BAKER BROS. ADVISORS LP 2.83M sh · $52.89M · Q2 2026
- MPM BioImpact LLC 2.42M sh · $45.20M · Q2 2026
- Elmind Capital, LP 1.47M sh · $27.42M · Q2 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held RLAY?
Bellevue Group AG has disclosed RLAY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Bellevue Group AG's current position in RLAY?
As of Q2 2026, Bellevue Group AG holds 6.19M shares of RLAY (RELAY THERAPEUTICS INC COM), valued at $115.74M, representing 2.44% of its reported portfolio and ranking #11.
Has Bellevue Group AG been buying or selling RLAY?
In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in RLAY. The position peaked in Q2 2026 at 6.19M shares.
Which other funds hold RLAY?
Other major institutional holders of RLAY include SB INVESTMENT ADVISERS (UK) LTD, Casdin Capital, PERCEPTIVE ADVISORS LLC, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.